Elie Isenberg-Grzeda1, Megan Johnson Shen2, Yesne Alici3, Jonathan Wills4, Christian Nelson3, William Breitbart3. 1. Department of Psychiatry, Sunnybrook Health Sciences Center, Toronto, ON, Canada. 2. Weill-Cornell Medical College, New York, NY, USA. 3. Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Information Systems, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
OBJECTIVE: Thiamine deficiency (TD) is increasingly recognized in medically ill patients. The prevalence of TD among cancer patients is unknown. This study aims to characterize the prevalence of TD among inpatients with cancer. METHODS: Retrospective chart review of patients admitted to a large cancer center who were referred for psychiatric consultation and whose serum thiamine concentration was measured. Patients with alcohol use were excluded. RESULTS: Among 217 patients with various cancer types, TD was found in 55.3%. Risk factors included fluorouracil-based chemotherapy, significant weight loss, and undergoing active cancer treatment. Almost all patients were normal weight, overweight, or obese, and few had concomitant vitamin B12 or folate deficiency. A total of 17.5% were receiving multivitamin supplementation. Nearly half (49.8%) did not receive empiric treatment with thiamine and among those who did, treatment delay occurred in the majority of cases (59.6%). Measurement of serum thiamine concentration preceded psychiatric consultation in only 10.6% of cases. CONCLUSIONS: Our findings suggest that TD is highly prevalent among inpatients with cancer, even among normal and overweight individuals, in the absence of other vitamin deficiencies, and while receiving multivitamin supplements. Several potential risk factors were identified, including active cancer treatment. Evaluation of TD was most commonly not initiated by oncologists. Failure to treat and treatment delay were common. Given these findings, oncologists must be vigilant about detecting TD among inpatients with cancer.
OBJECTIVE:Thiaminedeficiency (TD) is increasingly recognized in medically ill patients. The prevalence of TD among cancerpatients is unknown. This study aims to characterize the prevalence of TD among inpatients with cancer. METHODS: Retrospective chart review of patients admitted to a large cancer center who were referred for psychiatric consultation and whose serum thiamine concentration was measured. Patients with alcohol use were excluded. RESULTS: Among 217 patients with various cancer types, TD was found in 55.3%. Risk factors included fluorouracil-based chemotherapy, significant weight loss, and undergoing active cancer treatment. Almost all patients were normal weight, overweight, or obese, and few had concomitant vitamin B12 or folate deficiency. A total of 17.5% were receiving multivitamin supplementation. Nearly half (49.8%) did not receive empiric treatment with thiamine and among those who did, treatment delay occurred in the majority of cases (59.6%). Measurement of serum thiamine concentration preceded psychiatric consultation in only 10.6% of cases. CONCLUSIONS: Our findings suggest that TD is highly prevalent among inpatients with cancer, even among normal and overweight individuals, in the absence of other vitamin deficiencies, and while receiving multivitamin supplements. Several potential risk factors were identified, including active cancer treatment. Evaluation of TD was most commonly not initiated by oncologists. Failure to treat and treatment delay were common. Given these findings, oncologists must be vigilant about detecting TD among inpatients with cancer.
Authors: Stacy A Hanninen; Pauline B Darling; Michael J Sole; Aiala Barr; Mary E Keith Journal: J Am Coll Cardiol Date: 2006-01-17 Impact factor: 24.094
Authors: A Rufa; F Rosini; A Cerase; F Giannini; E Pretegiani; R Buccoliero; M T Dotti; A Federico Journal: Int J Neurosci Date: 2011-01-19 Impact factor: 2.292
Authors: Jonathan M Wai; Christopher Aloezos; Wenzhu B Mowrey; Sarah W Baron; Regina Cregin; Howard L Forman Journal: J Subst Abuse Treat Date: 2019-01-23
Authors: Zev M Nakamura; Allison M Deal; Donald L Rosenstein; Laura J Quillen; Stephanie A Chien; William A Wood; Thomas C Shea; Eliza M Park Journal: Contemp Clin Trials Date: 2020-06-30 Impact factor: 2.226
Authors: Xiaojing Liu; Daniel E Cooper; Ahmad A Cluntun; Marc O Warmoes; Steven Zhao; Michael A Reid; Juan Liu; Peder J Lund; Mariana Lopes; Benjamin A Garcia; Kathryn E Wellen; David G Kirsch; Jason W Locasale Journal: Cell Date: 2018-09-20 Impact factor: 41.582
Authors: Zev M Nakamura; Allison M Deal; Eliza M Park; Laura J Quillen; Stephanie A Chien; Kate E Stanton; Sean D McCabe; Hillary M Heiling; William A Wood; Thomas C Shea; Donald L Rosenstein Journal: J Psychosom Res Date: 2021-04-27 Impact factor: 4.620